Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Daoying Geng
18f-Fluorodeoxyglucose (FDG) PET/CT After Two Cycles of Neoadjuvant Therapy May Predict Response in HER2-negative, but Not in HER2-positive Breast Cancer
Oncotarget
Oncology
Related publications
Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer
Journal of Breast Disease
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
New England Journal of Medicine
Medicine
Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Dynamic Changes in CD44v-positive Cells After Preoperative Anti-Her2 Therapy and Its Correlation With Pathologic Complete Response in HER2-positive Breast Cancer
Oncotarget
Oncology
Anti-Her2 CD4+ T-Helper Type 1 Response Is a Novel Immune Correlate to Pathologic Response Following Neoadjuvant Therapy in HER2-positive Breast Cancer
Breast Cancer Research
Cancer Research
Oncology
Targeted Therapy for HER2 Positive Breast Cancer
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Prognostic Value of Tumor Heterogeneity on 18f-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients Receiving 500 Mg Fulvestrant: A Retrospective Study
Scientific Reports
Multidisciplinary
Positive Response to Neoadjuvant Cyclophosphamide and Doxorubicin in Topoisomerase II Nonamplified/Her2/Neu Negative/Polysomy 17 Absent Breast Cancer Patients
Cancer Management and Research
Oncology
Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?
Therapeutic Advances in Medical Oncology
Oncology
